Access
To read this story in full you will need to login or make a payment (see right).
Technology Feature
Nature 430, 113 (1 July 2004) | doi:10.1038/430113a
Open Innovation Challenges
- More Challenges
- Powered by:
nature jobs
Senior Executive- Finance Corporate Office
- Rhydburg Pharmaceuticals
- Selaqui-Dehradun India
Basic Science Medical Educators
- Texas Tech University Health Sciences Center
- El Paso, Texas, USA
Starting from scratch
Computational methods are being applied across the drug-development process from the earliest stages of drug design. "We're seeing a lot of companies who don't want to spend time and money on screening existing compound libraries," says Bart Wuurman, chief executive officer at De Novo Pharmaceuticals, a leading in silico drug-design company in Cambridge, UK.
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
